Mobilizing Bone Marrow Progenitor Cells, a Double Edge Sword

Landázuri, Natalia; Taylor, W. Robert

doi:10.1007/s10557-008-6125-8

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the effects of G-CSF therapy remain controversial, which may relate to discrepancies in protocols and methodology in those studies [24]. G-CSF has been used at a range of doses, including 10 μg/kg/d in humans [19,20,22], 50-100 μg/kg/d in rat models [6][7][8], and 100-300 μg/kg/d in mouse models [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Disassociation Between Left Ventricular Mechanical and Electrical Properties in Ischemic Rat Heart After G-CSF Treatment

Li¹,

Luo²,

Zhou³

et al. 2011

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Disassociation Between Left Ventricular Mechanical and Electrical Properties in Ischemic Rat Heart After G-CSF Treatment

Li¹,

Luo²,

Zhou³

et al. 2011

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

“…5) In particular view of safety concerns, clinical use of the several therapeutic angiogenesis using autologous bone marrow-or peripheral blood-derived MNCs have been accumulated, however, the superior efficacy of those cell therapies has not yet been achieved. 9,10,[14][15][16] Practical, less-invasive and easily applicable therapeutic angiogenesis remains to be established. Peripheral blood MNC Fig.…”

Section: Discussionmentioning

confidence: 99%

Autologous Peripheral Blood-Derived Mononuclear Cells Induced by Erythropoietin Improve Critical Ischemic Limbs

Kanbara

Kurobe

Kitaichi

et al. 2012

Annals of Vascular Diseases

View full text Add to dashboard Cite

Purpose: Efficient and secure collection of CD34+ cells are crucial for the angiogenic therapies. We have developed autologous peripheral blood-mononuclear cell (MNC) transplantation induced by erythropoietin (rhEPO) for critical ischemic limbs. Methods: Seven patients, including five with arteriosclerosis obliterans, one with Buerger's disease and one with progressive systemic sclerosis, underwent ten cell therapies. The first administration of rhEPO was performed two weeks before apheresis, and the second administration and blood donation were performed one week before apheresis to activate bone marrow. MNCs including CD34+ cells, isolated from peripheral blood by apheresis, were immediately injected intramuscularly into ischemic limbs. Results: The number of peripheral blood-CD34 + cells had significantly increased from 1.32 ± 0.83/microL, before the rhEPO induction, to 1.86 ± 0.94/microL, before the apheresis. The number of transplanted MNCs ranged between 0.5 × 10 9 and 16.5 × 10 9 , and that of CD34+ cells, between 0.1 × 10 6 and 12.7 × 10 6 , accounting for 0.02%-0.1% of MNCs. There were no serious complications. Finger ulcers with Buerger's disease were significantly improved one month after the transplantations, but the same or other ulcer(s) appeared 2-6 months later. Three patients had an improvement in rest pain, and one patient extended maximum pain-free walking distance. Conclusions: Erythropoietin-induced autologous peripheral blood-MNC transplantation is a useful and safe alternative for ischemic limbs.

show abstract

Mobilizing Bone Marrow Progenitor Cells, a Double Edge Sword

Cited by 2 publications

References 18 publications

Disassociation Between Left Ventricular Mechanical and Electrical Properties in Ischemic Rat Heart After G-CSF Treatment

Disassociation Between Left Ventricular Mechanical and Electrical Properties in Ischemic Rat Heart After G-CSF Treatment

Autologous Peripheral Blood-Derived Mononuclear Cells Induced by Erythropoietin Improve Critical Ischemic Limbs

Contact Info

Product

Resources

About